Cas:1823420-32-1 methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate manufacturer & supplier

Chemical Name:methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate

CAS.NO:1823420-32-1

Synonyms:methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate

Molecular Formula:C₈H₆BrN₃O₂

Molecular Weight:256.05614

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate Use and application,methyl 3-bromopyrazolo[1,5-a]pyrimidine-6-carboxylate technical grade,usp/ep/jp grade.

Related News: J&J’s top brass told the group that its shot holds up against the Delta variant compared with older versions of the virus. After 8 months, the vaccine presents a similar antibody and T-cell response to Delta as it does with other concerning variants, J&J reported. 1-(4-Aminophenyl)-5-methylpyrrolidin-2-one manufacturers The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus. 7-methoxy-1h-quinolin-2-one suppliers Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial. (4-bromo-2-chlorophenyl)-morpholin-4-ylmethanone vendor & factory Atom utilization is also better with biocatalysis; where two or more moieties on the same molecule have the capacity to undergo a particular reaction, biocatalytic processing guarantees that one site is consistently chosen over the other. ,The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus.